Comprehensive somatic detection with advanced oncology signatures
Leverage premium annotation databases for superior variant interpretation
Adjust panels on-the-fly to meet evolving clinical needs
Generate comprehensive clinical reports with all the insights you need at a glance
Molecular labs work tirelessly to decode the genetic complexities of cancer, turning NGS data into insights that guide patient care. Their expertise is essential and often time-sensitive.
SeqOne’s AI-powered bioinformatics suite is designed to support their work, helping streamline analysis and accelerate the path to precision oncology.
Advanced Bioinformatics for Somatic DNA Panel Analysis from FASTQ files.
Variant Calling
SNVs, CNVs, SVs, InDels
Biomarkers & Signatures
MSI
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal
Reference Genomes
Hg19 & Hg38
SomaCGP
SomaCGP supports NGS analysis of Comprehensive Genomic Profiling (CGP) from FASTQ files.
Variant Calling
SNVs, CNVs, SVs, InDels, exon skipping, DNA and RNA fusions
Biomarkers & Signatures
TMB, MSI, HRD
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal
Reference Genomes
Hg19 & Hg38
SomaHRD
SomaHRD provides Homologous Recombination Defect score from shallow WGS
Variant Calling
Interoperable with SomaVar and SomaCGP
Signature
Genomic Instabiity score
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal
Reference Genome
Hg19
SomaVar Tertiary
SomaVar tertiary supports annotation of variants from VCF files
Variant Calling
SNPs, InDels, CNVs, fusions
Wetlab Compatibility
AmoyDx, Pillar, ThermoFisher
SomaRNA
Supports RNA-seq data from targeted approaches to identify and view gene fusion events
Variant Calling
SomaVar pipeline
Biomarkers & Signatures
Fusions, exon skipping
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal, capture or amplicon technology
Reference Genome
Hg19
SomaVar LF
SomaLF provides analytical capabilities for low fraction somatic variant analysis from liquid biopsy
Variant Calling
SNVs, InDels, structural variants
Quality Control
UMI technology to detect variants from 0.1% VaF
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal
Reference Genomes
Hg19 & Hg38
SomaHemato
SomaHemato supports analysis of hematological cancer DNA panels from FASTQ files.
Variant Calling
FLT3-ITD, KMT2A-PTD, Gene fusions
Biomarkers & Signatures
IGHV mutational status for CLL, TP53
Instrument Compatibility
Illumina, MGI, Element Biosciences
Wetlab Compatibility
Universal
Reference Genomes
Hg19 & Hg38
Redefining HRD Testing in Ovarian Cancer
Homologous Recombination Deficiency (HRD) is a key biomarker for guiding PARP inhibitor therapy in ovarian and other cancers. But traditional HRD testing can be slow and unreliable, leading to delayed or inconclusive results when treatment decisions matter most. SomaHRD changes that.
Built for molecular labs, SomaHRD delivers rapid, high-confidence HRD results, ensuring oncologists get timely, actionable insights to personalize patient care.
Why Labs Choose SomaHRD
95% concordance with the PAOLA-1 Phase 3 clinical trial reference test
Reliable results with tumor content as low as 20%
Advanced genomic instability analysis integrating LGA, LPC, and BRCA1/2 assessment
See the Data Behind SomaHRD.
Download our White Paper for clinical validation details.
North West GLH’s journey to faster, more reliable HRD testing
One of the UK’s leading genomic labs, North West Genomic Laboratory Hub, revolutionized its HRD testing workflow with SeqOne—reducing turnaround time, improving accuracy, and optimizing resource allocation.
The result?
Faster, more reliable insights for guiding precision oncology treatments.
The big advantage of using SeqOne for us is how transparent the process is: we can get high-resolution information on each sample and understand in detail how the genomic instability score is calculated. This gives us additional confidence when reporting clinical results to the doctors and patients we serve.
